ADTL-EI1712

Cat. No.:	HY-138215
CAS No.:	2414916-45-1
Molecular Formula:	$C_{22}H_{18}Cl_2N_4O_2S_2$
Molecular Weight:	505.44
Target:	ERK
Pathway:	MAPK/ERK Pathway; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ADTL-EI1712 is a potent, orally active, and selective dual-target inhibitor of ERK1 and ERK5, inhibition rates of ERK1/5 at 1 μM are 93.54% and 89.35%, respectively. ADTL-EI1712 can induce regulated cell death, a form of cell death that relies on the activation of genetically encoded machinery, to overcome compensatory mechanism in specific cancer cells in vitro and in vivo[1].
In Vitro	ADTL-EI1712 shows antiproliferative activity against HL-60, MKN-74 and HeLa cells, with IC_{50} values of 1.26+0.57, 2.55+0.66, >50 μM, respectively[1]. ADTL-EI1712 (0.5 μM, 24 h) induces regulated cell death accompanied by autophagy in MKN-74 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ADTL-EI1712 (50 mg/kg, PO, once a day for 16 days) significantly inhibits the tumor volume in the xenograft mouse model of HL-60 and MKN-74 cells, while the antitumor effect of HeLa cells group was much weaker[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang G, et al. Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types. J Med Chem. 2020 Apr 23;63(8):3976-3995.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA